|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: ZNF720 |
Gene summary for ZNF720 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | ZNF720 | Gene ID | 124411 |
| Gene name | KRAB box domain containing 5 | |
| Gene Alias | ZNF720 | |
| Cytomap | 16p11.2 | |
| Gene Type | protein-coding | GO ID | GO:0006139 | UniProtAcc | Q7Z2F6 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 124411 | ZNF720 | LZE4T | Human | Esophagus | ESCC | 1.21e-06 | 2.58e-01 | 0.0811 |
| 124411 | ZNF720 | LZE7T | Human | Esophagus | ESCC | 4.53e-02 | 1.63e-01 | 0.0667 |
| 124411 | ZNF720 | LZE8T | Human | Esophagus | ESCC | 1.20e-02 | 1.24e-01 | 0.067 |
| 124411 | ZNF720 | LZE20T | Human | Esophagus | ESCC | 4.78e-04 | 1.44e-01 | 0.0662 |
| 124411 | ZNF720 | LZE24T | Human | Esophagus | ESCC | 1.07e-18 | 4.69e-01 | 0.0596 |
| 124411 | ZNF720 | LZE21T | Human | Esophagus | ESCC | 1.51e-03 | 1.99e-01 | 0.0655 |
| 124411 | ZNF720 | LZE6T | Human | Esophagus | ESCC | 1.36e-08 | 3.79e-01 | 0.0845 |
| 124411 | ZNF720 | P1T-E | Human | Esophagus | ESCC | 7.54e-06 | 3.50e-01 | 0.0875 |
| 124411 | ZNF720 | P2T-E | Human | Esophagus | ESCC | 2.04e-30 | 5.31e-01 | 0.1177 |
| 124411 | ZNF720 | P4T-E | Human | Esophagus | ESCC | 1.28e-23 | 5.07e-01 | 0.1323 |
| 124411 | ZNF720 | P5T-E | Human | Esophagus | ESCC | 3.71e-15 | 2.71e-01 | 0.1327 |
| 124411 | ZNF720 | P8T-E | Human | Esophagus | ESCC | 2.69e-25 | 4.22e-01 | 0.0889 |
| 124411 | ZNF720 | P9T-E | Human | Esophagus | ESCC | 3.70e-08 | 1.96e-01 | 0.1131 |
| 124411 | ZNF720 | P10T-E | Human | Esophagus | ESCC | 6.53e-11 | 1.85e-01 | 0.116 |
| 124411 | ZNF720 | P11T-E | Human | Esophagus | ESCC | 2.64e-08 | 2.48e-01 | 0.1426 |
| 124411 | ZNF720 | P12T-E | Human | Esophagus | ESCC | 2.99e-29 | 4.76e-01 | 0.1122 |
| 124411 | ZNF720 | P15T-E | Human | Esophagus | ESCC | 3.01e-16 | 3.69e-01 | 0.1149 |
| 124411 | ZNF720 | P16T-E | Human | Esophagus | ESCC | 2.84e-13 | 2.74e-01 | 0.1153 |
| 124411 | ZNF720 | P17T-E | Human | Esophagus | ESCC | 3.74e-02 | 1.75e-01 | 0.1278 |
| 124411 | ZNF720 | P20T-E | Human | Esophagus | ESCC | 6.38e-09 | 3.15e-01 | 0.1124 |
| Page: 1 2 3 4 5 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| ZNF720 | SNV | Missense_Mutation | c.353N>T | p.Glu118Val | p.E118V | Q7Z2F6 | protein_coding | deleterious(0) | possibly_damaging(0.873) | TCGA-EA-A3QE-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
| ZNF720 | SNV | Missense_Mutation | novel | c.136N>A | p.Ala46Thr | p.A46T | Q7Z2F6 | protein_coding | tolerated(0.2) | benign(0.109) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| ZNF720 | SNV | Missense_Mutation | novel | c.247N>G | p.Gln83Glu | p.Q83E | Q7Z2F6 | protein_coding | tolerated(0.24) | benign(0.003) | TCGA-A5-A2K2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Chemotherapy | taxol | SD |
| ZNF720 | SNV | Missense_Mutation | novel | c.70N>T | p.Asp24Tyr | p.D24Y | Q7Z2F6 | protein_coding | deleterious(0) | possibly_damaging(0.53) | TCGA-B5-A3FA-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| ZNF720 | SNV | Missense_Mutation | c.288A>C | p.Gln96His | p.Q96H | Q7Z2F6 | protein_coding | tolerated(0.08) | benign(0.442) | TCGA-BS-A0UF-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| ZNF720 | SNV | Missense_Mutation | novel | c.327N>T | p.Gln109His | p.Q109H | Q7Z2F6 | protein_coding | deleterious(0.03) | benign(0.009) | TCGA-E6-A1LX-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| ZNF720 | deletion | Frame_Shift_Del | c.189delG | p.Trp63Ter | p.W63* | Q7Z2F6 | protein_coding | TCGA-BS-A0UF-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |||
| ZNF720 | insertion | Frame_Shift_Ins | novel | c.380_381insAA | p.Ter127%3D | p.*127%3D | Q7Z2F6 | protein_coding | TCGA-2Y-A9H8-01 | Liver | liver hepatocellular carcinoma | Female | >=65 | I/II | Targeted Molecular therapy | sorafenib | PD | ||
| ZNF720 | insertion | Frame_Shift_Ins | novel | c.380_381insAA | p.Ter127%3D | p.*127%3D | Q7Z2F6 | protein_coding | TCGA-DD-AADL-01 | Liver | liver hepatocellular carcinoma | Male | <65 | I/II | Unknown | Unknown | SD | ||
| ZNF720 | SNV | Missense_Mutation | c.146N>T | p.Lys49Met | p.K49M | Q7Z2F6 | protein_coding | deleterious(0.01) | possibly_damaging(0.87) | TCGA-44-6147-01 | Lung | lung adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |